NM DRUG OVERDOSE PREVENTION QUARTERLY MEASURES REPORT THIRD QUARTER OF 2018 (2018Q3)
|
|
- Dominic Cross
- 5 years ago
- Views:
Transcription
1 NM DRUG OVERDOSE PREVENTION QUARTERLY MEASURES REPORT THIRD QUARTER OF 218 () Substance Abuse Epidemiology Section Prescription Drug Overdose Prevention Program Injury and Behavioral Epidemiology Bureau Epidemiology and Response Division This report is produced quarterly to track indicators related to drug overdose prevention. The indicators reported here allow for the tracking of three key interventions for prescription drug overdose: improving prescribing of controlled substances, increasing the availability of treatment for opioid dependence, and the increasing availability of nalxone in the community. This report is based on calendar quarters: Q1 is January-March of the calendar year. Data for this report were drawn from several sources: 1. The Prescription Monitoring Program (PMP) operated by the NM Board of Pharmacy, which collects data on every controlled substance prescription filled in New Mexico. 2. New Mexico Medicaid in the Human Services Department, for data on methadone treatment paid by Medicaid, and for data on claims paid for naloxone prescriptions at pharmacies. 3. The State Opioid Treatment Authority in the Human Services Department for data on methadone treatment programs operating in New Mexico. 4. The NM Department of Health Syringe Services Program for data on naloxone distributed via syringe exchange sites 5. The Behavioral Health Services Division in the Human Services Department for data on naloxone distributed through Office of Substance Abuse Prevention programs.
2 Patients Patients I. New Mexico Prescription Monitoring Program (PMP) Measures Patients with Controlled Substance, Opioid and Benzodiazepine Prescriptions, , 247, ,763 Controlled substance patients 253,69 236,4 229,964 2, 163, ,71 172,187 Patients receiving opioids 154, ,364 1, 93,526 9,169 89,622 87,49 85,73 Patients receiving benzodiazepines 217Q3 217Q4 218Q1 218Q2 Patients with Overlapping Prescriptions, , 4,5 4, 4,67 4,447 4,87 3,752 3,684 3,5 3, 2,5 2,95 2,73 2,543 2,386 2,311 2, 1,5 1, 5 Overlapping prescriptions of opioids from different prescribers (>=1 days total overlap) Overlapping prescriptions of benzodiazepines from different prescribers (>=1 days total overlap) 217Q3 217Q4 218Q1 218Q2 Page 2
3 Patients Prescriptions filled Patients I. New Mexico Prescription Monitoring Program (PMP) Measures Patients with Concurrent Opioids and Benzodiazepines (>=1 days overlap), , 2, 22,913 21,91 21,115 19,767 18,655 1, 217Q3 217Q4 218Q1 218Q2 5, 45, 4, 35, 3, 25, 2, 15, 1, 5, High Dose Prescriptions, ,25 41,732 4,554 39,331 37,558 37,51 35,47 34,888 33,658 32,738 Number of high dose (>=9 MME/day) opioid prescriptions excluding buprenorphine/naloxone Number of high-dose(>=4 DME/day) benzodiazepine prescriptions filled 217Q3 217Q4 218Q1 218Q2 5 Patients with Multiple Prescribers and Pharmacies, or more prescribers or 4 or more pharmacies in 3 months 25 3,42 3,45 2,873 2,627 2, Q3 217Q4 218Q1 218Q2 Page 3
4 I. New Mexico Prescription Monitoring Program (PMP) Measures Totals Year and Quarter 217Q3 218Q2 218Q2 vs % 217Q3 vs Total number of controlled substance patients 247, ,4 229, % -7.% Number of patients receiving opioids 163, , , % -9.3% Number of opioid prescriptions filled (excluding buprenorphine/naloxone) 353,26 33,51 275, % -22.% Number of buprenorphine/naloxone prescriptions filled 2,641 22,824 23,742 4.% 15.% Number of high dose (>=9 MME/day) opioid prescriptions excluding buprenorphine/naloxone Total MME of opioids filled - excluding buprenorphine/naloxone 43,25 39,331 37, % -13.2% 323,328,2 296,877,63 288,65,589-3.% -1.9% Total MME/prescription-day % 8.5% Number of patients receiving benzodiazepines 93,526 87,49 85,73-2.8% -9.% Number of benzodiazepine prescriptions filled 27,82 192,93 187, % -9.6% Number of high-dose(>=4 DME/day) benzodiazepine prescriptions filled 37,51 33,658 32, % -12.7% Total DME of benzodiazepines filled 115,5,327 13,53,87 99,752,73-3.6% -13.3% Total DME/patient 1,23 1,183 1, % -4.6% SOURCE OF DATA: NM Prescription Monitoring Program (PMP), NM Prescribers with at least 2 controlled substance patients MME = Morphine Milligram Equivalent; reference at htpp:// DME = Diazepam Milligram Equivalent; reference at 24 Page 4
5 I. New Mexico Prescription Monitoring Program (PMP) Measures Number of Patients with: Year and Quarter 217Q3 218Q2 218Q2 vs 217Q3 vs High dose opioids (>=9 MME/day) 15,491 14,65 13, % -14.9% High dose benzodiazepines (>=4 DME/day) 16,61 14,87 14, % -13.7% Opioids >=9 days and <9% of days in past 6 months 23,671 2,46 19, % -16.9% Opioids >=9% of days in past 6 months 31,124 31,31 3,73-1.% -1.3% Benzodiazepines >=9 days and <9% of days in past 6 months 26,181 23,123 22,29-3.6% -14.9% Benzodiazepines >=9% of days in past 6 months 25,319 24,984 24,473-2.% -3.3% Overlapping prescriptions of opioids from different prescribers (>=1 days total overlap) 4,67 3,752 3, % -21.1% Overlapping prescriptions of benzodiazepines from different prescribers (>=1 days total overlap) 2,95 2,386 2, % -2.4% Concurrent opioid and benzodiazepines (>=1 days overlap) High dose opioids (>=9 MME/day) plus benzodiazepines 22,913 19,767 18, % -18.6% 4,441 3,643 3, % -23.% Multiple prescribers and pharmacies: 4 or more prescribers or 4 or more pharmacies in 3 months 3,42 2,627 2, % -2.6% New Opioid Patients with at least 3 days of coverage in the past 3 months New Benzodiazepine Patients with at least 3 days of coverage in the past 3 months 3,79 3,43 3,12-8.3% -17.7% 4,842 4,421 4,37-2.6% -11.% SOURCE OF DATA: NM Prescription Monitoring Program (PMP), NM Prescribers with at least 2 controlled substance patients Page 5
6 Prescribers I. New Mexico Prescription Monitoring Program (PMP) Measures New Mexico Prescribers with at least 2 controlled substance patients: Year and Quarter 217Q3 218Q2 218Q2 vs 217Q3 vs Total active controlled substance prescribers 3,147 3,76 3,32-1.4% -3.7% Prescribers with at least 5% high dose of opioid prescriptions, excluding treatment prescribers Prescribers with at least 5% high dose of benzodiazepine prescriptions Prescribers with at least 25% of patients having concurrent opioids and benzodiazepines Some PMP Use: Requested reports on at least 25% of patients estimated to require them Zero PMP Use: Requested no PMP reports on patients filling Controlled Substances Number of Patients with PMP reports requested by practitioners % of Chronic opioid users with a PMP request in the past 3 months* % of Chronic benzodiazepine users with a PMP request in the past 3 months* % of New Opioid Patients with a PMP request in the past 3 months** % of New Benzodiazepine Patients with a PMP request in the past 3 months** % 11.3% % -6.8% % -32.% 1,18 1,164 1, % 12.4% % -21.5% 112, ,99 121,57-3.6% 8.% 61.6% 66.3% 66.1% -.3% 7.3% 38.8% 43.% 42.1% -2.2% 8.5% 17.3% 19.3% 2.5% 6.5% 18.4% 2.% 23.% 22.8% -1.2% 13.7% *Chronic users are those with at least 9 days of coverage in six months. **New patients are those with more than 4 days of coverage in the quarter and none in the prior quarter. SOURCE OF DATA: NM Prescription Monitoring Program (PMP), NM Prescribers with at least 2 controlled substance patients 2 Treatment (buprenorphine/naloxone) prescribers with at least 1 Treatment Patients, Q3 217Q4 218Q1 218Q2 Source: NM Prescription Monitoring Program Page 6
7 Patients II. Medication Assisted Treatment (Buprenorphine/naloxone and methadone) Measures Treatment (buprenorphine/naloxone) prescribers with at least 1 treatment patients Year and Quarter 217Q3 218Q2 218Q2 vs 217Q3 vs % 33.1% Buprenorphine/naloxone patients (>=1 days) Buprenorphine/naloxone prescriptions filled Total Practitioners with DATA Waiver Nurse Practitioners and PA's with DATA Waiver Medicaid Methadone Treatment Number of distinct individuals with methadone claims paid by NM Medicaid Number of distinct NM Medicaid providers of methadone 5,26 5,895 6,83 3.2% 15.6% 2,641 22,824 23,742 4.% 15.% % 18.3% % 74.2% 4,764 5,152 5, % 12.% %.% Methadone Treatment Programs by Survey Date 3/217 1/218 3/218 4/218 8/218 Number of Methadone Treatment Programs Number of Methadone Treatment Patients in those Programs 5,531 5,275 5,662 6,76 6,258 DATA Waivered provider data are as of the last month of the quarter Sources: Buprenorphine/naloxone data: NM Prescription Monitoring Program Methadone data: NM Human Services Department, State Opioid Treatment Authority; NM Medicaid DATA Waivered providers: US DEA Diversion Control Division Total Buprenorphine/Naloxone Treatment Patients, Buprenorphine/naloxone patients (>=1 days) 5,26 5,415 5,668 5,895 6,83 217Q3 217Q4 218Q1 218Q2 Source: NM Prescription Monitoring Program Page 7
8 Count III. Naloxone Distribution and Usage Measures Total number of NM Government Program Naloxone Enrollments Year and Quarter 217Q3 218Q2 % 218Q2 vs % 217Q3 vs 1,423 1,48 2, % 7.1% Total Number of NM Naloxone Doses distributed Total Number of NM Reported Reversals 5,238 8,334 8, % 54.9% % 56.4% Year and Quarter 217Q3 218Q2 % 218Q2 vs % 217Q3 vs Pharmacies Presenting Medicaid Naloxone Claims Number of Medicaid Naloxone Claims Processed Number of Police Agencies Carrying Naloxone % 15.5% 1,174 1,698 1, % 58.1% 73 #DIV/! -1.% Number Some naloxone of Pharmacies doses were Stocking given Naloxone to organizations and may n/anot have n/a been distributed n/a in that quarter. Reported Reversals are not necessarily individual level data, as one person could have overdosed and been reversed more than once. Data on reversals are combined across several agencies and programs, and the definition of a reversal may vary. An outpatient pharmacy could present claims in more than one quarter. The total number was obtained by counting each pharmacy once. There were 369 outpatient Pharmacies with a NM address in 217 according to the Board of Pharmacy. All law enforcement agencies have been contacted about naloxone training and use. The data reported reflect the number of agencies where at least some officers are carrying naloxone. Sources: NM DOH Programs; NM HSD/BHSD Programs; NM Medicaid 9, 8, 7, 6, 5, 4, 3, 2, 1, Total Naloxone Enrollees, Doses and Reversals, Total Number of NM Naloxone Doses distributed Total number of NM Government Program Naloxone Enrollments 8,334 8,115 Reported Reversals 8,3 5,238 6,334 2,42 1,423 1,361 1,781 1, Q3 217Q4 218Q1 218Q2 Page 8
NM DRUG OVERDOSE PREVENTION QUARTERLY MEASURES REPORT FOURTH QUARTER OF 2017 (2017Q4)
NM DRUG OVERDOSE PREVENTION QUARTERLY MEASURES REPORT FOURTH QUARTER OF 217 () Substance Abuse Epidemiology Section Prescription Drug Overdose Prevention Program Injury and Behavioral Epidemiology Bureau
More informationNM DRUG OVERDOSE PREVENTION QUARTERLY MEASURES REPORT THIRD QUARTER OF 2017 (2017Q3)
NM DRUG OVERDOSE PREVENTION QUARTERLY MEASURES REPORT THIRD QUARTER OF 217 () Substance Abuse Epidemiology Section Prescription Drug Overdose Prevention Program Injury and Behavioral Epidemiology Bureau
More informationNew Mexico Board of Pharmacy Prescription Monitoring Program (PMP)
New Mexico Board of Pharmacy Prescription Monitoring Program (PMP) PDMP West Regional Meeting PMP Collaboration with the NM Department of Health April 26, 2018 New Mexico Board of Pharmacy Prescription
More informationApril 26, New Mexico Board of Pharmacy Prescription Monitoring Program (PMP) New Mexico Board of Pharmacy Prescription Monitoring Program (PMP)
New Mexico Board of Pharmacy Prescription Monitoring Program (PMP) New Mexico Nurse Practitioner Council New Mexico Board of Pharmacy Prescription Monitoring Program (PMP) Peter Ryba, PharmD PMP Director
More information4/24/15. New Mexico s Prescription Monitoring Program. Carl Flansbaum, RPh. PMP Director New Mexico Board of Pharmacy. New Mexico and the PMP
New Mexico s Carl Flansbaum, RPh. PMP Director New Mexico Board of Pharmacy New Mexico and the PMP In 2012, New Mexico had the 3 nd Highest Overdose Death Rate in Nation.! 492 Deaths or a rate of 23.6
More informationWhat is the strategy?
What is the strategy? Multi-pronged approaches to reducing the health consequences of opioid use, New York City Northeast Epidemiology Conference Public health approach Track drug use and associated health
More informationThe STOP Measure. Safe and Transparent Opioid Prescribing to Promote Patient Safety and Reduced Risk of Opioid Misuse FEBRUARY 2018
The STOP Measure Safe and Transparent Opioid Prescribing to Promote Patient Safety and Reduced Risk of Opioid Misuse FEBRUARY 2018 AHIP s Safe, Transparent Opioid Prescribing (STOP) Initiative Methodology
More informationBUPRENORPHINE/NALOXONE THERAPY DOM CLINICAL GUIDELINES AND RECOMMENDED CHANGES
BUPRENORPHINE/NALOXONE THERAPY DOM CLINICAL GUIDELINES AND RECOMMENDED CHANGES BACKGROUND In September 2012, the Division of Medicaid (DOM) implemented criteria through electronic prior authorization (PA)
More informationThe Wisconsin Prescription Drug Monitoring Program. WI PDMP Timeline. PDMP Overview. What is a PDMP? PDMPs Across the Nation. Wisconsin.
The Wisconsin Prescription Drug Monitoring Program Wisconsin Nurses Association Jail Health Care Conference May 21, 2018 WI PDMP Timeline PDMP Overview January 2013 WI PDMP operational April 2017 WI epdmp
More informationData-Driven Multidisciplinary Approaches to Reduce Prescription Drug Abuse in Kentucky
Data-Driven Multidisciplinary Approaches to Reduce Prescription Drug Abuse in Kentucky http://uknow.uky.edu/content/kentucky-awarded-grant-prescription-drugabuse-prevention-program Data-Driven Multidisciplinary
More informationPain: Assessment, Non-Opioid Treatment Approaches and Opioid Management
Quality Improvement Support: Pain: Assessment, Non-Opioid Treatment Approaches and Opioid Management The Aims and Measures section is intended to provide protocol users with a menu of measures for multiple
More information2 nd Bernalillo County Opioid Abuse Accountability Summit Data Series January 8, 2015
2 nd Bernalillo County Opioid Abuse Accountability Summit Data Series January 8, 2015 Harris Silver, MD Co-chair, Bernalillo County Opioid Abuse Accountability Initiative Deaths per 100,000 population
More informationAddressing the Opioid Crisis Workgroup: Treatment and Overdose Prevention
The Accountable Community for Health of King County Addressing the Opioid Crisis Workgroup: Treatment and Overdose Prevention May 7, 2018 1 Opiate Treatment & Overdose Prevention Project Goal Immediate:
More informationCDC Guideline for Prescribing Opioids for Chronic Pain
National Center for Injury Prevention and Control CDC Guideline for Prescribing Opioids for Chronic Pain John Halpin, MD, MPH Medical Officer Division of Unintentional Injury Prevention Prescription Drug
More informationOpioid Prescribing Improvement Program
Opioid Prescribing Improvement Program Jeff Schiff, MD, MBA, Medical Director of Minnesota Health Care Programs Sarah Rinn, MPH, Opioid Prescribing Improvement Program Coordinator Agenda Opioid Prescribing
More informationThe Wisconsin Prescription Drug Monitoring Program
The Wisconsin Prescription Drug Monitoring Program DHS 2018 WI Opioid Forum April 12, 2018 Learning Objectives 1. How the WI epdmp supports healthcare professionals in making informed prescribing, dispensing
More informationSection I. Short-acting opioid Prior Authorization Criteria
Request for Prior Authorization for Opioid analgesics Website Form www.highmarkhealthoptions.com Submit request via: Fax - 1-855-476-4158 Requests for opioid analgesics may be subject to prior authorization
More informationMedicaid and the Opioid Crisis
Medicaid and the Opioid Crisis Erica Floyd Thomas Bureau Chief of Medicaid Policy Agency for Health Care Administration Presented to: Medical Care Advisory Committee March 20, 2018 1 Florida Medicaid Covers
More informationDoctor Shopping Behavior and the Diversion of Opioid Analgesics:
Doctor Shopping Behavior and the Diversion of Opioid Analgesics: 2008-2012 A report prepared for The Executive Office of The President Office of National Drug Control Policy Ron Simeone Simeone Associates,
More informationIdaho DUR Board Meeting Minutes. Committee Member Present: David Agler, M.D., Dawn Berheim, Pharm.D., Perry Brown, M.D., Matthew Hyde, Pharm.D.
Idaho DUR Board Meeting Minutes Date: January 25, 2018 Time: 9am-12:00pm Location: Idaho Medicaid, 3232 Elder Street, Boise, Idaho, Conference Room D-West Moderator: David Agler, M.D. Committee Member
More informationNew Mexico Prescription Monitoring Program Data Report
New Mexico Prescription Monitoring Program Data Report 26 213 Table of Contents Introduction... 2 Methods... 3 Results... 4 Demographics... 5 Opioids... 5 Benzodiazepines... 6 Trends over time... 7 Opioids...
More informationDrug Overdose in New Mexico
Drug Overdose in New Mexico Behavioral Health Collaborative January 8, 2015 Jim Davis, MA Drug Epidemiologist New Mexico Department of Health Deaths per 100,000 persons 30.0 Drug Overdose Death Rates New
More informationOpioid Overdose in Oregon Report to the Legislature
SEPTEMBER 2018 Opioid Overdose in Oregon Report to the Legislature This report summarizes the burden of opioid overdose among Oregonians as required by ORS 432.141. It describes Oregon s progress in reducing
More informationMedicare Part D Prescription Opioid Policies for 2019 Information for Pharmacists
CENTERS FOR MEDICARE & MEDICAID SERVICES Medicare Part D Prescription Opioid Policies for 2019 Information for Pharmacists Background Opioid medications are effective at treating certain types of pain,
More informationOpioid Report Card. opioid oversight from MN Dept of Health
Opioid Report Card opioid oversight from MN Dept of Health Charles Reznikoff, MD Addiction Medicine, Internal Medicine Charles.reznikoff@hcmed.org Nov 2018 Disclosures I have no relevant financial disclosures
More informationGreenbrier County. West Virginia Board of Pharmacy Prescription Opioid Problematic Prescribing Indicators County Report
West Virginia Board of Pharmacy Prescription Opioid Problematic Prescribing Indicators Report The West Virginia Violence and Injury Prevention Program ( VIPP), in collaboration with the West Virginia Board
More informationOregon Opioid Overdose Prevention Initiative
Oregon Opioid Overdose Prevention Initiative Katrina Hedberg, MD, MPH Health Officer & State Epidemiologist Oregon Public Health Division Oregon Association of Hospitals & Health Systems February 2017
More informationMandatory PDMP Use PDMP Use STATE Prescriber Dispenser Conditions, if applicable
Arizona Amends worker s compensation statute to require physicians to request PMP information within two (2) business days of writing or dispensing prescriptions for at least a 30 day supply of an opioid
More informationPutnam County. West Virginia Board of Pharmacy Prescription Opioid Problematic Prescribing Indicators County Report
West Virginia Board of Pharmacy Prescription Opioid Problematic Prescribing Indicators Report The West Virginia Violence and Injury Prevention Program ( VIPP), in collaboration with the West Virginia Board
More informationOpioid Use and Other Trends
Opioid Use and Other Trends National Overview Across the nation communities are struggling with a devastating increase in the number of people misusing opioid drugs, leading many to identify the current
More informationBlue Cross of Idaho Addresses State s Opioid Issue
Blue Cross of Idaho Addresses State s Opioid Issue BY THE NUMBERS - Opioid Management page 3 THE PROBLEM - How Preventing Pain Hurt Us page 4 THE SOLUTIONS - Idaho State Board Of Pharmacy Prescription
More informationMaine s Response to the Opiate Crisis. Christopher Pezzullo, DO State Health Officer Maine DHHS Maine CDC November 12, 2016
Maine s Response to the Opiate Crisis Christopher Pezzullo, DO State Health Officer Maine DHHS Maine CDC November 12, 2016 Required Disclosure Text Font typically Times New Roman at least 20 point Try
More informationPrescription Monitoring Program (PMP)
06/15/2018 FACT SHEET Implementation of Enacted Prescribing Limits and Requirements and Relevant Opioid Prescribing Laws and Rules Background: The 2016 law (Chapter 488) makes five major changes to opioid
More informationBree Collaborative AMDG Opioid Prescribing Guidelines Workgroup. Opioid Prescribing Metrics - DRAFT
Bree Collaborative AMDG Opioid Prescribing Guidelines Workgroup Opioid Prescribing Metrics - DRAFT Definitions: Days Supply: The total of all opioid prescriptions dispensed during the calendar quarter
More informationCDC Guideline for Prescribing Opioids for Chronic Pain. Centers for Disease Control and Prevention National Center for Injury Prevention and Control
CDC Guideline for Prescribing Opioids for Chronic Pain Centers for Disease Control and Prevention National Center for Injury Prevention and Control THE EPIDEMIC Chronic Pain and Prescription Opioids 11%
More informationPDMP Track: Linking and Mapping PDMP Data. Gillian Leichtling Acumentra Health Chris Baumgartner, WA State Dept. of Health
PDMP Track: Linking and Mapping PDMP Data Gillian Leichtling Acumentra Health Chris Baumgartner, WA State Dept. of Health Disclosure Statement Gillian Leichtling and Chris Baumgartner have disclosed no
More informationCentral Oregon Pain Standards Task Force
Central Oregon Pain Standards Task Force For 2018 Oregon Pain + Addiction Treatment Conference KIM SWANSON, PH.D. CHAIR PAIN STANDARDS TASK FORCE Disclosures Kim Swanson, Ph.D. is a full time salaried
More informationNYSHFA/NYSCAL 16 th Annual Nurse Leadership Conference. Timothy J. Dewey Sr. Investigator NYS Bureau of Narcotic Enforcement.
NYSHFA/NYSCAL 16 th Annual Nurse Leadership Conference Timothy J. Dewey Sr. Investigator NYS Bureau of Narcotic Enforcement May 2, 2018 1 May 2, 2018 2 Bureau Overview May 2, 2018 3 HISTORY 1850--Bureau
More informationNew Medicare Part D Prescription Opioid Policies for 2019 Information for Prescribers
CENTERS FOR MEDICARE & MEDICAID SERVICES New Medicare Part D Prescription Opioid Policies for 2019 Information for Prescribers Background CMS understands the magnitude of the nation s opioid epidemic and
More informationMassachusetts Responds to the Opioid Epidemic Using Data To Inform Policy and Programs. Monica Bharel, MD MPH Commissioner of Public Health
Massachusetts Responds to the Opioid Epidemic Using Data To Inform Policy and Programs Monica Bharel, MD MPH Commissioner of Public Health Data For Massachusetts 2017 Q2 Quarterly Report and Chapter 55
More informationRevised 9/30/2016. Primary Care Provider Pain Management Toolkit
Revised 9/30/2016 Primary Care Provider Pain Management Toolkit TABLE OF CONTENTS 1. INTRODUCTION Page 1 2. NON-OPIOID SERVICES &TREATMENTS FOR CHRONIC PAIN Page 2 2.1 Medical Services Page 2 2.2 Behavioral
More informationWashington State PMP Data Mapping Project
Washington State PMP Data Mapping Project 2014 Category 3 Grant Harold Rogers Category 3 Grantee Meeting February 25, 2015 Washington State BACKGROUND: OPIOID ISSUES AND PLANNING 2 WA Unintentional Opioid
More informationOpioid Management of Chronic (Non- Cancer) Pain
Optima Health Opioid Management of Chronic (Non- Cancer) Pain Guideline History Original Approve Date 5/08 Review/Revise Dates 11/09, 9/11, 9/13, 09/15, 9/17 Next Review Date 9/19 These Guidelines are
More informationOpioid Review and MAT Clinic CDC Guidelines
1 Opioid Review and MAT Clinic CDC Guidelines January 10, 2018 Housekeeping Use chat feature to inform everyone who s at your clinic Click chat on Zoom option bar Chat Everyone the names of those who are
More informationIdaho DUR Board Meeting Minutes
Idaho DUR Board Meeting Minutes Date: January 21, 2016 Time: 9am-1:30pm Location: Idaho Medicaid, 3232 Elder Street, Boise, Idaho, Conference Room D-West Moderator: Mark Turner, M.D. Committee Members
More informationOCCUPATIONAL AND PROFESSIONAL LICENSING MEDICINE AND SURGERY PRACTITIONERS MANAGEMENT OF PAIN AND OTHER CONDITIONS WITH CONTROLLED SUBSTANCES
TITLE 16 CHAPTER 10 PART 14 OCCUPATIONAL AND PROFESSIONAL LICENSING MEDICINE AND SURGERY PRACTITIONERS MANAGEMENT OF PAIN AND OTHER CONDITIONS WITH CONTROLLED SUBSTANCES 16.10.14.1 ISSUING AGENCY: New
More informationThe Morbidity and Mortality of Kansas Drug Epidemic
The Morbidity and Mortality of Kansas Drug Epidemic Fan Xiong, MPH Senior Epidemiologist Kansas Board of Pharmacy Kansas Data-Driven Prevention Initiative Program Kansas Department of Health and Environment,
More informationThe Oregon Opioid Initiative. State Pain & Opioid Conference Prescription Drug Monitoring May 2018 Lisa Millet, Public Health Division
The Oregon Opioid Initiative State Pain & Opioid Conference Prescription Drug Monitoring May 2018 Lisa Millet, Public Health Division Disclosure No disclosures 2 Learning Objectives Learner will be able
More informationPrescription Drug Monitoring Program
California Department of Justice Prescription Drug Monitoring Program May, 2016 Health and Safety Code section 11165. (a) To assist health care practitioners in their efforts to ensure appropriate prescribing,
More informationNEW MEXICO DEPARTMENT OF HEALTH Administrative Manual ADMINISTRATION
Chapter NEW MEXICO DEPARTMENT OF HEALTH Administrative Manual ADMINISTRATION EFFECTIVE: Policy REVISED: 4/13/9 draft NALOXONE DISTRIBUTION POLICY I. PURPOSE: This New Mexico Department of Health (NMDOH)
More informationPrescription Opioid Overdose in Oregon: A public health perspective
Prescription Opioid Overdose in Oregon: A public health perspective Katrina Hedberg, MD, MPH Health Officer & State Epidemiologist Oregon Public Health Division Oregon Health Authority All-Cause Mortality,
More informationBarbour County. West Virginia Board of Pharmacy Prescription Opioid Problematic Prescribing Indicators County Report Barbour County
County West Virginia Board of Pharmacy Prescription Opioid Problematic Prescribing Indicators County Report County The West Virginia Violence and Injury Prevention Program ( VIPP), in collaboration with
More informationMandatory PDMP Use PDMP Use STATE Prescriber Dispenser Conditions, if applicable
Arizona Amends worker s compensation statute to require physicians to request PMP information within two (2) business days of writing or dispensing prescriptions for at least a 30 day supply of an opioid
More informationMaine s New Opioid Prescribing Law & the Opioid Crisis: Implications for Providers
Maine s New Opioid Prescribing Law & the Opioid Crisis: Implications for Providers Gordon H. Smith, Esq., Executive Vice President Maine Medical Association May 3, 2016 Facing the Opioid Crisis Today Opioid
More informationMingo County. West Virginia Board of Pharmacy Prescription Opioid Problematic Prescribing Indicators County Report
West Virginia Board of Pharmacy Prescription Opioid Problematic Prescribing Indicators Report The West Virginia Violence and Injury Prevention Program ( VIPP), in collaboration with the West Virginia Board
More informationPREVENTING OPIATE OVERDOSES IN SCHOOLS. Head 2 Toe 2017 April 20, 2017 Winona Stoltzfus BSN, MD, School Health Officer and Acting RHO SE Region
PREVENTING OPIATE OVERDOSES IN SCHOOLS Head 2 Toe 2017 April 20, 2017 Winona Stoltzfus BSN, MD, School Health Officer and Acting RHO SE Region WHY IS THIS EVEN A QUESTION FOR SCHOOLS? In 2014, 467,000
More informationTaos Alive. Improving a Community in Pain By Julie Martinez CPS
Taos Alive Improving a Community in Pain By Julie Martinez CPS About Taos County About Taos Alive Community Based Coalition 12 Sectors (Youth, Parents, Business, Media, Schools, Youth Serving Organizations,
More informationOpioid epidemic and PEHP
Opioid epidemic and PEHP Agenda Overview of opioid crisis Utah perspective PEHP: clinical interventions Impact of interventions Why are we here? In the 1990s, the medical establishment came to believe
More informationUsing the NC Controlled Substances Reporting System to Identify Providers Manifesting Unusual Prescribing Practices
Using the NC Controlled Substances Reporting System to Identify Providers Manifesting Unusual Prescribing Practices Prevention Research Center Penn State December 2, 2015 Chris Ringwalt, DrPH* Sharon Schiro,
More informationPrescription Drug Monitoring Program (PDMP) Delaware. Information contained in this presentation is accurate as of November 2017
Prescription Drug Monitoring Program (PDMP) Delaware Information contained in this presentation is accurate as of November 2017 Dr. Michael C. Dejos, PharmD, BCPS, LSSBB 2 Acknowledgements Christian Ruffin,
More informationIdentification of Specific Drugs and Drug Diversion in Drug Overdose Fatalities
Identification of Specific Drugs and Drug Diversion in Drug Overdose Fatalities Svetla Slavova, PhD Sara LaMantia, MS Terry Bunn, PhD Tracey Corey, MD 2016 Safe States Annual Meeting April 13, 2016, Albuquerque,
More informationProposed Changes to Existing Measure for HEDIS : Use of Opioids at High Dosage (UOD)
Proposed Changes to Existing Measure for HEDIS 1 2020: Use of Opioids at High Dosage (UOD) NCQA seeks comments on proposed revisions to the Use of Opioids at High Dosage HEDIS measure. The current measure
More informationTargeting an Epidemic: Opioid Prescribing Patterns by County in New York State
Targeting an Epidemic: Opioid Prescribing Patterns by County in New York State DECEMBER 2017 Improving the state of New York s health Background O pioid abuse is a public health crisis for the nation and
More informationIn-House Chronic Pain and Opioid Use Reporting Guide
In-House Chronic Pain and Opioid Use Reporting Guide Table of Contents Updated Date: 05/04/2018 By Simon Parker-Shames Table of Contents 0 Introduction 1 Types of Measures 1 Quick Start Packages: 2 Starter
More informationThe Regulatory Agency Will See You Now Kevin L. Zacharoff, MD Disclosures Nothing to Disclose
The Regulatory Agency Will See You Now Kevin L. Zacharoff, MD Disclosures Nothing to Disclose 1 Learning Objectives Identify pain treatment related regulatory agencies Discuss the changing role of regulatory
More informationPocahontas County. West Virginia Board of Pharmacy Prescription Opioid Problematic Prescribing Indicators County Report
West Virginia Board of Pharmacy Prescription Opioid Problematic Prescribing Indicators Report The West Virginia Violence and Injury Prevention Program ( VIPP), in collaboration with the West Virginia Board
More informationKanawha County. West Virginia Board of Pharmacy Prescription Opioid Problematic Prescribing Indicators County Report
West Virginia Board of Pharmacy Prescription Opioid Problematic Prescribing Indicators Report The West Virginia Violence and Injury Prevention Program ( VIPP), in collaboration with the West Virginia Board
More informationOpioid Use and Misuse: History, Trends, And The Oregon Opioid Initiative
Opioid Use and Misuse: History, Trends, And The Oregon Opioid Initiative John W. McIlveen, Ph.D., LMHC, State Opioid Treatment Authority, Oregon Health Authority, Addictions and Mental Health Division
More information2. Is this request for a preferred medication? Y N
Pharmacy Prior Authorization AETA BETTER HEALTH EW JERSE (MEDICAID) Opioids Long-Acting and Short-Acting (Medicaid) This fax machine is located in a secure location as required by HIPAA regulations. Complete/review
More informationThe Epidemiology of Opioid Abuse. Thomas Dobbs, MD, MPH Mississippi State Department of Health
The Epidemiology of Opioid Abuse Thomas Dobbs, MD, MPH Mississippi State Department of Health 1/12/2018 ACKNOWLEDGEMENTS DRUG ABUSE WORKING GROUP MISSISSIPPI STATE DEPARTMENT OF HEALTH Manuela Staneva,
More informationThe Opioid Epidemic: The State of the State
JOINT LEGISLATIVE COMMITTEE ON HEALTH AND HUMAN SERVICES The Opioid Epidemic: The State of the State Dr. Mandy Cohen, Dr. Susan Kansagra Department of Health and Human Services Nov. 14, 2017 3 PEOPLE DIE
More informationAcademic Medical School: Implementing Curriculum in Chronic Pain and Opioid Misuse. Jill M Williams, MD
Academic Medical School: Implementing Curriculum in Chronic Pain and Opioid Misuse Pain, Pain Management and the Opioid Epidemic Symposium Jill M Williams, MD Professor Psychiatry Director, Division Addiction
More informationPRESCRIPTION DRUG MONITORING PROGRAM
PRESCRIPTION DRUG MONITORING PROGRAM ST. LOUIS COUNTY Q2 2017 Contents Executive Summary... 2 User Registration & System Utilization... 4 Dispensation Rates... 6 Dispensation Rates by Geography... 6 Dispensation
More informationState, District, or Territory Criteria for Mandatory Enrol ment or Query of PDMP
State, District, or Territory Alabama Arizona Arkansas Criteria for Mandatory Enrollment or Query of PDMP Before renewing an Alabama Controlled Substances Certificate, the applicant shall have a current
More informationClinical Guidelines and Coverage Limitations for Medication Assisted Treatment (MAT)
Clinical Guidelines and Coverage Limitations for Medication Assisted Treatment (MAT) For Apple Health clients served Fee-for-Service and through contracted Medicaid Managed Care Organizations Updated January
More informationPDMP Tools to Identify Red Flag Situations
PDMP Tools to Identify Red Flag Situations Prescription Drug Monitoring Programs CBI Baltimore, MD February 7, 2017 Grant Carrow, Ph.D. Project Consultant The Heller School for Social Policy and Management
More informationNew Guidelines for Opioid Prescribing
New Guidelines for Opioid Prescribing What They Mean for Elders with Chronic Pain Manu Thakral, PhD, ARNP Kaiser Permanente Washington Health Research Institute Kaiser Permanente Washington Health Research
More informationD. Todd Bess, PharmD 1
s Program as a Tool to Improve Patient Care and Fight the Drug Epidemic D. Todd Bess, Pharm.D. Director April 12, 2018 Disclosure Information I have no financial relationships to disclose. I will not discuss
More informationManagement of Pain - A Comparison of Current Guidelines
Management of Pain - A Comparison of Current Guidelines The Centers for Disease Control and Prevention (CDC) released a guideline in 2016 regarding the prescribing of opioids for chronic non-cancer pain
More informationMayors Opioid Summit PATTERNS AND TRENDS OF THE OPIOID EPIDEMIC IN BROWARD COUNTY TYPES OF OPIOIDS DEFINITION OF OPIOID. Pill Press from China
The Opioid Epidemic In Broward County 8/24/217 Mayors Opioid Summit PATTERNS AND TRENDS OF THE OPIOID EPIDEMIC IN BROWARD COUNTY Jim Hall Senior Epidemiologist Center for Applied Research on Substance
More information3. Has the patient had a sustained improvement in Pain or Function (e.g. PEG scale with a 30 percent response from baseline)?
Pharmacy Prior Authorization AETA BETTER HEALTH KETUCK Opioids Long-Acting and Short-Acting (Medicaid) This fax machine is located in a secure location as required by HIPAA regulations. Complete/review
More informationWashington State s Overdose Epidemic
Caleb Banta-Green PhD MPH MSW Senior Research Scientist- Alcohol and Drug Abuse Institute Affiliate Associate Professor- School of Public Health Affiliate Faculty- Harborview Injury Prevention & Research
More informationOpioids: What You Should Know About Opioid Prescribing. Denis G. Patterson, DO Nevada State Medical Association October 19, 2016
Opioids: What You Should Know About Opioid Prescribing Denis G. Patterson, DO Nevada State Medical Association October 19, 2016 Contact Information Denis G. Patterson, DO Nevada Advanced Pain Specialists
More informationLegislative & Regulatory Update Brad Young, RxPlus Government Affairs
Legislative & Regulatory Update 2018 Brad Young, RxPlus Government Affairs Disclosures Brad Young reports no actual or potential conflicts of interest associated with this presentation. 2 Learning Objectives
More informationPRESCRIBING GUIDELINES
Ohio Department of Health RESPONSE TO OHIO S PRESCRIPTION DRUG OVERDOSE EPIDEMIC: PRESCRIBING GUIDELINES MIPA CONFERENCE PREVENTING INJURY: FROM RESEARCH TO PRACTICE TO PEOPLE SEPTEMBER 30, 2013 Christy
More informationChallenges for U.S. Attorneys Offices (USAO) in Opioid Cases
Challenges for U.S. Attorneys Offices (USAO) in Opioid Cases Overview On August 2, 2017, U.S. Attorney General Jeff Sessions announced a pilot program whereby a new federal data analysis program is being
More informationPrescribing Opioids in the Opioid Epidemic. Scott Woffinden, PA-C Jason Chapman, JD
Prescribing Opioids in the Opioid Epidemic Scott Woffinden, PA-C Jason Chapman, JD What's the Problem? http://www.zdoggmd.com/blank-script-taylor-swift-parody/ What's the Problem? CDC 115 Americans die
More informationTHE PROS & CONS OF THE CDC GUIDELINES FOR SAFE OPIOID PRESCRIBING
THE PROS & CONS OF THE CDC GUIDELINES FOR SAFE OPIOID PRESCRIBING Ernest J Dole, PharmD, PhC, FASHP, BCPS Clinical Pharmacist University of New Mexico Hospitals And Clinical Associate Professor University
More informationCLINICAL POLICY Clinical Policy: Extended Release Opioid Analgesics
Reference Number: AZ.CP.PMN.97 Effective Date: 02.11 Last Review Date: 02.18 Line of Business: Medicaid- AHCCCS Revision Log See Important Reminder at the end of this policy for important regulatory and
More informationThe Opioid Crisis: Effectiveness of State Responses
The Opioid Crisis: Effectiveness of State Responses Gordon H. Smith, Esq. Maine Medical Association American Society of Medical Association Counsel Mauna Lani Bay, November 2017 Opioids: the difficult
More informationBERNALILLO COUNTY OPIOID ABUSE ACCOUNTABILITY SUMMIT Turning the Curve on Opioid Abuse in Bernalillo County
BERNALILLO COUNTY OPIOID ABUSE ACCOUNTABILITY SUMMIT Turning the Curve on Opioid Abuse in Bernalillo County NMPHA Annual Conference April 2, 2014 Marsha McMurray-Avila Coordinator, Bernalillo County Community
More informationTaking Action Against Opioids through Research and Best Practice
Taking Action Against Opioids through Research and Best Practice Session 1002-7, March 6, 2018 Darshak Sanghavi, MD, Chief Medical Officer, OptumLabs Molly Jeffery, PhD, Scientific Director of Emergency
More informationScott Kirby, M.D, Medical Director, North Carolina Medical Board. Chris Ringwalt, Dr.P.H., Senior Scientist, UNC Injury Prevention Research Center
Using the NC Controlled Substances Reporting System to Identify Providers with Unusual Prescribing Practices: A Partnership of the State of North Carolina, UNC Injury Prevention Center, and the N.C. Medical
More informationPrescription Drug Monitoring Program Update. Rebecca R. Poston, BPharm., MHL Program Manager August 26, 2017
Prescription Drug Monitoring Program Update Rebecca R. Poston, BPharm., MHL Program Manager August 26, 2017 Objectives Brief historical overview of opioids Review of PDMP information Discuss ideas from
More informationWHAT YOU NEED TO KNOW TO ABOUT AB 474
WHAT YOU NEED TO KNOW TO ABOUT AB 474 PRESENTED BY: NEVADA STATE BOARD OF OSTEOPATHIC MEDICINE 2275 Corporate Circle, Suite 210 Henderson, NV 89074 702-732-2147 Fax 702-732-2079 Web Site: www.bom.nv.gov
More informationTaking Action Against Opioids through Research and Best Practice
Taking Action Against Opioids through Research and Best Practice Session 7, March 6, 2018 Darshak Sanghavi, MD, Chief Medical Officer, OptumLabs Molly Jeffery, PhD, Scientific Director of Emergency Care
More informationArkansas Prescription Monitoring Program
Arkansas Prescription Monitoring Program ONE YEAR UPDATE Scott Pace, Pharm.D., Esq. Special Thanks Thanks to Denise Robertson at the Arkansas Department of Health for supplying the PMP data for this presentation
More informationScO.S. Academic Detailing for Safer Prescribing
ScO.S. Academic Detailing for Safer Prescribing Sarah Ball, PharmD Research Assistant Professor MUSC College of Medicine September 6, 2017 Megan Pruitt, PharmD SCORxE Clinical Pharmacy Consultant MUSC
More informationBureau of Narcotic Enforcement Update. Recent Changes to New York State s Controlled Substance Act
Bureau of Narcotic Enforcement Update Recent Changes to New York State s Controlled Substance Act Number of of drug-induced deaths deaths compared compared with other with types of deaths, US, 1999-2006
More information